GURU.Markets stock price, segment price, and overall market index valuation
The company's share price enGene Holdings Inc.
Shares of enGene, a biotech company developing gene therapy, are a bet on its innovative drug delivery platform. The price trajectory depends on news from preclinical and early clinical trials.
Share prices of companies in the market segment - Pharma immune
enGene Holdings is a biotechnology company developing a non-invasive platform for delivering gene therapy directly to intestinal mucosal cells to treat various diseases. We've classified it in the "Pharma-Immune" segment. The chart below shows the overall dynamics in the cutting-edge gene therapy sector, where researchers are exploring new ways to deliver drugs.
Broad Market Index - GURU.Markets
enGene is a biotech company developing non-viral gene therapies that are delivered directly to tissue to treat diseases. As part of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ENGN - Daily change in the company's share price enGene Holdings Inc.
The price fluctuations of enGene, a biopharmaceutical company, reflect the dynamics of the gene therapy sector. Change_co demonstrates high sensitivity to clinical trial results. This indicator is an important component of formulas on System.GURU.Markets that assess volatility in the innovative medicine sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
enGene Holdings Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ENGN, which focuses on gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
enGene is a biopharmaceutical company developing gene therapy. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with enGene's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization enGene Holdings Inc.
enGene Holdings Inc.'s annual performance is driven by its innovative method of delivering gene therapy directly to the intestinal mucosa. Its 12-month market cap depends on progress in early clinical trials, where the company must demonstrate the safety and efficacy of its non-systemic treatment approach.
Annual dynamics of market capitalization of the market segment - Pharma immune
enGene, a recent IPO, is developing innovative gene therapy. Its performance reflects investor confidence in its scientific platform. The chart below shows how its high potential and early-stage risks compare to a sector dominated by giants with established products.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
enGene is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization enGene Holdings Inc.
As a gene therapy company, enGene's value will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of clinical trials of its innovative drug delivery technology, the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Pharma immune
enGene Holdings is developing a non-invasive platform for delivering gene therapy directly to intestinal cells, avoiding systemic exposure. This is a groundbreaking approach to treatment. The gene therapy sector chart reflects overall investor interest in this revolutionary field, allowing one to assess the potential and risks of enGene's unique technology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
enGene Holdings is developing gene therapy for direct tissue delivery. This is cutting-edge technology, but it has not yet been commercialized. The company's stock price is entirely dependent on investor confidence in its scientific potential and news about clinical trials. Its correlation with overall market sentiment is minimal, as the chart will show.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization enGene Holdings Inc.
enGene, a company developing gene therapies delivered directly to tissue, is at the forefront of biotechnology. Its weekly stock price is almost exclusively driven by news of clinical trials and regulatory decisions, which is typical for companies at such an early stage of development.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Biotech companies developing gene therapy, like enGene, are at the forefront of science. News in this field often impacts the entire industry. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives enGene's unique gene delivery platform compared to competing technologies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
enGene Holdings develops innovative gene therapy delivered directly to tissue. This is a cutting-edge, yet risky, area of biotechnology. This chart demonstrates how the company's shares operate in a world of their own, where a single lab announcement can overturn any market trend.
Market capitalization of the company, segment and market as a whole
ENGN - Market capitalization of the company enGene Holdings Inc.
enGene Holdings' market capitalization chart reflects investors' bets on its innovative gene therapy delivery method. Its dynamics reflect the market's belief that its "gene pill" technology will make gene therapy non-invasive and more accessible. Its value reflects the platform's potential for treating various diseases, including bladder cancer.
ENGN - Share of the company's market capitalization enGene Holdings Inc. within the market segment - Pharma immune
enGene Holdings is an innovative biotech company developing non-invasive gene therapy methods for treating immune system disorders. In its leading segment, its market capitalization reflects the potential of its unique platform. The company's market weight reflects the potential of its technology to transform approaches to treating a wide range of diseases.
Market capitalization of the market segment - Pharma immune
The chart below shows the overall market capitalization of the biotech sector specializing in immune therapy. For enGene, with its innovative non-invasive gene delivery platform, this line demonstrates the scale of the scientific revolution. The rising chart reflects the influx of capital into technologies that could transform approaches to treating a wide range of diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
enGene Holdings develops non-invasive methods for delivering gene therapy to intestinal cells. Its market capitalization is a bet on a revolutionary, injection-free treatment. This represents the market share that investors are willing to allocate to this fundamentally new approach to medicine.
Book value capitalization of the company, segment and market as a whole
ENGN - Book value capitalization of the company enGene Holdings Inc.
enGene Holdings develops innovative gene therapy. Its book value represents its financial and scientific capital. It consists of cash for research and the value of its unique gene delivery platform. How has this capital changed on the path to developing new drugs? The chart below shows.
ENGN - Share of the company's book capitalization enGene Holdings Inc. within the market segment - Pharma immune
enGene Holdings Inc. is a pioneer in orally delivered gene therapy. Its unique approach requires its own resources: development laboratories and pilot production lines to create its innovative product. The chart shows the company's share of the R&D infrastructure necessary for the development of non-invasive gene therapy.
Market segment balance sheet capitalization - Pharma immune
enGene, a gene therapy company, has a lightweight R&D business. It focuses on developing its unique drug delivery platform. The biotech sector's BCap_Seg chart serves as a backdrop to its strategy of being agile and focused on science, not manufacturing.
Book value of all companies included in the broad market index - GURU.Markets
enGene Holdings' capital isn't its factories, but a unique technology for delivering gene therapy directly to mucosal cells. Its assets are patents and research data, which form the basis for future drugs. The chart shows how this intangible yet innovative asset plays out in the world of biotechnology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - enGene Holdings Inc.
enGene's balance sheet is its R&D capital. Its entire market value is a premium for its unique gene therapy delivery technology in a pill form. The schedule is a bet that this revolutionary delivery approach will be successful and become a game-changer for the industry.
Market to book capitalization ratio in a market segment - Pharma immune
enGene is a biotech company developing non-invasive gene therapy methods. Its high valuation on this chart reflects its breakthrough technology, which could make gene therapy more accessible if clinical trials are successful.
Market to book capitalization ratio for the market as a whole
enGene Holdings develops non-invasive gene therapy. The company's primary asset is its unique drug delivery technology. Its market capitalization is based on expectations of future clinical trial success. This chart clearly demonstrates how the market values scientific potential rather than tangible assets.
Debts of the company, segment and market as a whole
ENGN - Company debts enGene Holdings Inc.
enGene Holdings, a clinical-stage biotech developing gene therapies, uses equity to fund its expensive research. Debt instruments may be used to advance trials. This chart shows how the company manages its finances on the long road to potentially developing a new class of drugs.
Market segment debts - Pharma immune
enGene Holdings is a clinical-stage biotech company developing gene therapies for direct tissue delivery. Financing such cutting-edge and risky developments requires significant equity capital. This chart will show whether the company is pursuing the industry-standard, debt-free development model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio enGene Holdings Inc.
enGene Holdings develops gene therapy, one of the most advanced and capital-intensive areas of medicine. This chart shows the company's reliance on external funding for its research. It highlights the high risk and enormous potential inherent in companies operating at the forefront of the biotech revolution.
Market segment debt to market segment book capitalization - Pharma immune
enGene Holdings is developing an innovative platform for delivering gene therapy directly to mucosal cells. This is a cutting-edge, yet highly complex, approach to medicine. This chart illustrates how the biotech sector as a whole is using debt to finance revolutionary but risky technologies, and how enGene compares.
Debt to book value of all companies in the market
enGene Holdings develops innovative gene therapies, one of the most capital-intensive areas of medicine. This chart shows the overall market leverage. It helps investors understand how the company's financial strategy for raising funds for long-term clinical trials is consistent with the high risks and standards of the biotech industry.
P/E of the company, segment and market as a whole
P/E - enGene Holdings Inc.
enGene Holdings is developing a non-invasive platform for delivering genes to intestinal cells to treat various diseases. This chart shows how the market is valuing its innovative approach to gene therapy. The company's valuation depends not on profits, but on the success of clinical trials and the potential of its unique delivery technology.
P/E of the market segment - Pharma immune
enGene Holdings develops innovative gene therapy. This chart shows the average valuation for the biotech sector. It emphasizes that enGene is valued not by current profits, but by the potential of its unique non-invasive delivery platform, which the market may value at a significant premium to the average.
P/E of the market as a whole
enGene Holdings Inc. is a biotech company developing a non-viral gene therapy platform that delivers therapeutic genes directly to mucosal cells. This chart reflects investors' overall risk appetite. It helps understand whether ENGN's high valuation is based on faith in its innovative technology or is driven by overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company enGene Holdings Inc.
enGene Holdings is developing an innovative platform for delivering gene therapy directly to mucosal cells. Future revenue depends on the success of this technology in clinical trials. This chart shows market expectations regarding the potential of this new approach for treating a wide range of diseases.
%20P%2FE%20enGene%20Holdings%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-enGene-Holdings-Inc.&v=1772650224726 "Chart of the company's future (projected) P/E enGene Holdings Inc.")
Future (projected) P/E of the market segment - Pharma immune
enGene Holdings is developing an innovative non-viral platform for delivering genes directly to mucosal cells, which could open up new possibilities in gene therapy. The data here reflects analysts' collective bets on the success of this unique technology. It's a barometer of expectations for the company's potential to achieve a breakthrough in this complex field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772650224765 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
enGene Holdings is developing innovative gene therapy delivered directly to tissue. This is a cutting-edge technology with high risk. This graph of overall investor sentiment shows the market appetite for funding fundamental research that could transform the treatment of many diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772650224807 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit enGene Holdings Inc.
enGene Holdings is developing an innovative platform for delivering genes directly to intestinal mucosal cells to treat various diseases. This chart illustrates the financial implications of cutting-edge gene therapy. It shows investments in a technology that could unlock new treatment options without systemic exposure.
Profit of companies in the market segment - Pharma immune
enGene Holdings is a biotechnology company developing gene therapies for direct tissue delivery, which could make treatment safer and more effective. Currently in the clinical stage, it exemplifies investment in cutting-edge science. Its potential success could significantly impact profitability in the gene therapy niche, reflecting progress in the field.
Overall market profit
enGene Holdings is a biotech company developing an innovative platform for delivering gene therapy directly into cells. Success depends on scientific results. The overall state of the economy, shown in this chart, is critically important because it determines sentiment in financial markets. In good times, investors are more willing to fund risky but promising technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company enGene Holdings Inc.
enGene Holdings is developing a non-invasive platform for delivering gene therapy directly to the intestinal mucosa. This chart reflects analysts' speculative revenue expectations. The forecast is contingent on successful proof-of-concept of their innovative technology in clinical trials.
%20profit%20of%20the%20company%20enGene%20Holdings%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-enGene-Holdings-Inc.&v=1772650225255 "Graph of future (projected) profit of the company enGene Holdings Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
enGene Holdings is developing an innovative, non-viral platform for gene therapy delivered directly to target tissues. The profitability projections for this cutting-edge sector, shown in the chart, reflect the high expectations of investors. This chart provides context for assessing how disruptive enGene's technology could be if proven safe and effective.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772650225291 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
enGene Holdings is a biotechnology company developing gene therapy for delivery directly to mucosal tissue. This is an innovative approach that requires significant investment. The availability of capital for such cutting-edge, yet risky, developments is highly dependent on overall market conditions, which improve with positive economic forecasts, as illustrated in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772650225307 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - enGene Holdings Inc.
enGene Holdings is a biotech company developing a unique platform for delivering genes directly to the intestinal lining to treat various diseases. This chart shows the premium investors are paying for its potential, betting that its non-invasive approach to gene therapy will be a breakthrough.
P/S market segment - Pharma immune
enGene Holdings is a biotechnology company developing a non-invasive platform for delivering genes directly to the intestinal mucosa to treat immune diseases. This metric reflects the average revenue estimate for the sector and helps understand the market premium for this innovative and potentially breakthrough approach to gene therapy.
P/S of the market as a whole
enGene Holdings is developing a non-invasive platform for delivering gene therapy directly to the intestinal mucosa, avoiding systemic injections. This chart provides context for understanding how investors value companies with existing revenue streams, which is important when analyzing biotech companies with breakthrough but unproven technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company enGene Holdings Inc.
enGene Holdings is a biotech company developing a non-viral platform for tissue-directed gene therapy. This chart reflects investors' high valuation of its potential future revenue. This valuation is a bet on the breakthrough nature of its technology and its potential application in the treatment of various diseases.
%20P%2FS%20enGene%20Holdings%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-enGene-Holdings-Inc.&v=1772650225447 "The graph of the company's future (projected) P/S enGene Holdings Inc.")
Future (projected) P/S of the market segment - Pharma immune
enGene Holdings is a biotech company developing non-viral gene therapies for local delivery. This chart compares market expectations for its future revenue with other immune pharma companies. This valuation reflects investor confidence in the potential of its unique gene delivery platform for treating diseases such as bladder cancer.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772650225483 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
enGene Holdings is a clinical-stage biotechnology company developing non-viral gene therapy. Its value depends on the success of its innovative drug delivery platform. This graph of enGene's overall economic expectations is merely a backdrop, while its value is driven by scientific breakthroughs that have the potential to transform treatment approaches.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772650225491 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales enGene Holdings Inc.
This chart shows the revenue of enGene Holdings, a company developing non-invasive gene therapy methods. Being in the clinical stage, the company has no commercial revenue. Any financial income reflected here likely comes from strategic partnerships with large pharmaceutical companies that help fund expensive clinical trials.
Sales of companies in the market segment - Pharma immune
enGene Holdings is a biotech company developing a non-viral gene therapy platform that delivers therapeutic genes directly to mucosal cells. This chart shows revenue in the immunological pharmaceuticals sector. It reflects the cutting edge of gene medicine, where innovative delivery systems like the one enGene is developing can make therapy safer.
Overall market sales
enGene Holdings is developing a non-invasive gene therapy for delivery directly to the intestinal mucosa. The success of this innovative technology depends on the results of clinical trials. The overall economic growth illustrated by this graph ensures the long-term financial stability of healthcare systems that may become potential customers for such therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company enGene Holdings Inc.
enGene Holdings is developing a groundbreaking approach to gene therapy, delivering drugs non-invasively through a special capsule. This projected revenue chart reflects enormous, yet speculative, expectations. Its growth is driven by analysts' belief that this unique technology will prove its worth in clinical trials and revolutionize medicine.
%20sales%20of%20the%20company%20enGene%20Holdings%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-enGene-Holdings-Inc.&v=1772650225566 "Schedule of future (projected) sales of the company enGene Holdings Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
enGene Holdings is a biotechnology company developing a non-invasive platform for delivering genes directly to the intestinal mucosa to treat immune diseases. This chart shows projected revenue for the immunopharmaceutical sector, reflecting interest in innovative gene therapy methods that could transform treatment approaches.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772650225584 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
enGene Holdings develops innovative gene therapy. The company's success is determined by scientific breakthroughs and future regulatory approvals. The positive economic outlook, reflected in this chart, creates a favorable funding environment for the biotech sector, which is critical for such capital-intensive research companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772650225599 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality enGene Holdings Inc.
enGene Holdings develops innovative gene therapy delivered directly to tissue. As a clinical-stage company, it relies on investment capital. This chart shows the intensity of its research, expressed in operating expenses. This represents the cost of creating a platform capable of transforming treatment approaches.
Market segment marginality - Pharma immune
enGene Holdings is a biotech company developing a non-viral platform for delivering gene therapy directly to the intestinal mucosa. This chart shows its financial performance in the context of the industry. For a company in the development stage, outperforming competitors in terms of profitability may be due to upfront payments from major pharmaceutical partners.
Market marginality as a whole
enGene Holdings is a biotechnology company developing an innovative platform for gene therapy delivered directly to tissue. Its success depends on breakthroughs in science and medicine, not on the state of the economy, as reflected in this chart. Successful demonstration of the safety and efficacy of their technology could revolutionize the treatment of many diseases.
Employees in the company, segment and market as a whole
Number of employees in the company enGene Holdings Inc.
enGene Holdings is a biotech company developing a non-viral gene therapy platform. This graph shows the team of scientists working on this innovative approach. The growth in staff is a direct indicator of progress in preclinical research and preparation for clinical trials, a key milestone for the company.
Share of the company's employees enGene Holdings Inc. within the market segment - Pharma immune
enGene Holdings is developing an innovative orally delivered gene therapy platform. Currently in clinical trials, its core asset is its scientific team. This chart highlights its R&D-focused model: the tiny proportion of employees in the sector indicates that its value is created in the lab, not on the production line.
Number of employees in the market segment - Pharma immune
enGene Holdings is developing an innovative non-viral platform for delivering gene therapy directly to mucosal cells. This graph reflects cutting-edge research in the field of genetic engineering. A small team of scientists is focused on proof of concept. Success of this technology could lead to exponential growth, but for now, it is a science-intensive startup.
Number of employees in the market as a whole
enGene Holdings develops innovative gene therapy delivered directly to tissue. Its team is comprised of specialists at the intersection of biotechnology and pharmacology. This employment graph illustrates how such highly specialized companies create unique jobs for the scientific elite, and their growth depends on R&D investment rather than macroeconomic conditions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company enGene Holdings Inc. (ENGN)
enGene Holdings is developing an innovative technology for delivering gene therapy directly to the intestinal mucosa, thereby avoiding systemic side effects. This chart illustrates the enormous cost per scientist. It's a striking example of how, in biotech, market valuation reflects the uniqueness and potential of a platform created by a small team.
%20of%20the%20company%20enGene%20Holdings%20Inc.%20(ENGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-enGene-Holdings-Inc.-ENGN&v=1772650225864 "Chart of market capitalization per employee (in thousands of dollars) of the company enGene Holdings Inc. (ENGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
enGene Holdings develops non-invasive gene therapy methods. In this revolutionary field of medicine, the company's value is a bet on the future success of the technology. This chart shows the premium investors are placing on each employee working on the unique gene delivery platform, compared to the average for the biopharmaceutical industry.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772650225958 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
enGene Holdings develops non-invasive gene therapy methods. This metric reflects a business at the cutting edge of science. Its market capitalization is based entirely on the promise of its unique gene delivery technology. Even a small team of scientists could be worth hundreds of millions if their approach proves effective.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772650225982 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company enGene Holdings Inc. (ENGN)
enGene Holdings is a clinical-stage biotech company developing non-viral gene therapies. This is cutting-edge science. They have no sales profit. This chart shows a loss per employee. This is typical for biotech and reflects the high cost of R&D in one of the most complex areas of modern medicine.
%20Chart%20enGene%20Holdings%20Inc.%20(ENGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-enGene-Holdings-Inc.-ENGN&v=1772650225994 "Company Profit Per Employee (in thousands of dollars) Chart enGene Holdings Inc. (ENGN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
enGene Holdings is a biotech company developing a unique platform for delivering gene therapy directly to tissue. Currently in the clinical stage, it is not profitable. This metric reflects the R&D budget burn per employee, allowing investors to compare the capital intensity of their platform with other gene therapy approaches.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772650226010 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
enGene Holdings is a biotech company specializing in gene therapy for immune diseases. This is a knowledge-intensive industry that requires significant and long-term investment in R&D. This graph likely reflects the negative cost of maintaining a team of highly qualified scientists and conducting complex studies before a product is approved.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772650226025 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee enGene Holdings Inc. (ENGN)
enGene Holdings is a biotech company developing gene therapies for direct tissue delivery. This schedule is typical for a clinical-stage company. The lack of revenue per employee means all efforts are focused on proving the safety and efficacy of their innovative platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-enGene-Holdings-Inc.-ENGN&v=1772650226042 "Sales chart per company employee enGene Holdings Inc. (ENGN)")
Sales per employee in the market segment - Pharma immune
enGene (ENGN) is a biotech company developing a platform for delivering gene therapy (DNA-based drugs) directly to cells in the mucosal lining (e.g., the intestines). This chart shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their unique R&D platform compared to other biotechs in the gene therapy field.
Sales per employee for the market as a whole
enGene Holdings is a biotechnology company developing a platform for delivering gene therapy (DLYB) directly to mucosal cells for the treatment of gastrointestinal diseases. This is an R&D business. The company has no commercial revenue. This metric does not currently reflect efficacy, but it serves as a benchmark for future commercial success.
Short shares by company, segment and market as a whole
Shares shorted by company enGene Holdings Inc. (ENGN)
enGene Holdings is a biotech company developing gene therapies for direct delivery to organs. This chart shows bearish bets. Bears are betting on the risks associated with the new platform. A failure in early clinical trials or safety issues could completely devalue the company.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-enGene-Holdings-Inc.-ENGN&v=1772650226101 "Short Shares Chart for the Company enGene Holdings Inc. (ENGN)")
Shares shorted by market segment - Pharma immune
enGene Holdings is a biotech company developing non-viral gene therapy delivery methods. This chart shows bearish bets. The "shorts" here represent bets that their innovative drug delivery platform will prove ineffective or unsafe in clinical trials.
Shares shorted by the overall market
enGene Holdings is developing non-invasive methods for delivering gene therapy into cells. This is a revolutionary approach to medicine, but it is still in the research phase. This chart shows the overall level of pessimism in the market. When investors are fearful, biotech stocks that are still far from commercialization become extremely vulnerable to sell-offs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator enGene Holdings Inc. (ENGN)
enGene Holdings is a clinical-stage biotech company. The stock is extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-enGene-Holdings-Inc.-ENGN&v=1772650226147 "RSI 14 indicator chart for the company's stock enGene Holdings Inc. (ENGN)")
RSI 14 Market Segment - Pharma immune
enGene (ENGN) is a biotech company, a "gene therapy engineer." Their platform (EDV) delivers "drugs" (DNA/RNA) directly to cells in the mucosal lining (e.g., the bladder). RSI_14_Seg for "Pharma-immune" (biotech) shows the overall sentiment. It helps us understand: is ENGN's volatility a reflection of their platform or just general hype?
RSI 14 for the overall market
enGene (ENGN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ENGN (enGene Holdings Inc.)
enGene (ENGN) is a biotech company developing non-viral gene therapies delivered orally or locally. This chart shows the average target price. It reflects analysts' speculative valuation of this innovative delivery platform and its potential for treating bladder cancer.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ENGN-enGene-Holdings-Inc.&v=1772650226230 "A chart showing analyst consensus forecasts for the expected stock price. ENGN (enGene Holdings Inc.)")
The difference between the consensus estimate and the actual stock price ENGN (enGene Holdings Inc.)
enGene is a biotech company whose specialty isn't the genes themselves, but their delivery. They've developed a platform (EDV) for non-viral local delivery of gene therapy (for example, to the bladder for cancer treatment), which should be safer. This chart shows how much analysts believe in this unique delivery technology and their clinical data.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ENGN-enGene-Holdings-Inc.&v=1772650226288 "A chart showing the difference between the consensus forecast and the actual stock price. ENGN (enGene Holdings Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
enGene Holdings is a biotech company developing innovative gene therapies for delivering drugs directly to the intestinal or bladder wall. This chart shows general expectations for the immunotherapy sector, reflecting experts' confidence in this unique R&D platform.
Analysts' consensus forecast for the overall market share price
enGene (ENGN) is a biopharmaceutical company developing "virus-free" gene therapy. Their technology enables drug delivery directly into cells without the use of viral vectors. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, but extremely risky and long-term research platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index enGene Holdings Inc.
enGene is a clinical-stage biotech company working on non-viral gene therapy. Their signature approach is delivering genes (drugs) directly to the mucosal lining (for example, the bladder) for cancer treatment. This graph represents a pure R&D bet. It likely reflects the market's confidence in their unique delivery technology and their early clinical data.
AKIMA Market Segment Index - Pharma immune
enGene (ENGN) is a clinical-stage biotech and a pioneer in gene therapy; the company is developing a unique non-viral gene delivery platform (dPEG) for direct delivery to the mucosa (for example, to the bladder for cancer treatment). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough (R&D platform) model (ENGN) differentiate it from the average pharma company?
The AKIM Index for the overall market
enGene is a biotech company developing non-viral gene therapy for local tissue delivery (bladder). Its key asset is detalimogene. This chart, reflecting the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this platform technology in cancer treatment.
